Yantai Dongcheng Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") announced that its wholly-owned subsidiary, Yantai Dongcheng Northern Pharmaceutical Co., Ltd. (hereinafter referred to as "Dongcheng Northern"), has received the "Acceptance Notice" issued by the National Medical Products Administration regarding the marketing authorization application for injectable nirmatrelvir. The relevant details are as follows:
002675SZSE
🚨 Material Event
Announcement on the Acceptance of the Application for Marketing Authorization of Injectable Nirmatrelvir by the National Medical Products Administration
✨ AI Summary
Yantai Dongcheng Pharmaceutical Group Co., Ltd. announced that its subsidiary received acceptance from the National Medical Products Administration for the marketing authorization application of injectable nirmatrelvir. The drug is indicated for conditions such as disseminated intravascular coagulation (DIC) and has a registered specification of 50mg. The company will continue to advance the application process while disclosing relevant information to investors.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.